Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications <a href="https://www.researchtopractice.com/YiR2024/NontargetedLung" rel="noopener noreferrer" target="_blank">here</a>.

Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here.

Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation.&nbsp;CME information and select publications <a href="https://www.researchtopractice.com/YiR2024/NontargetedLung" rel="noopener noreferrer">here</a>.

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Share Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

Sign up to save your podcasts

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances